Resverlogix Corp. (TSE:RVX) – Stock analysts at Zacks Investment Research issued their Q2 2017 earnings estimates for shares of Resverlogix Corp. in a research note issued on Monday. Zacks Investment Research analyst J. Vandermosten expects that the firm will post earnings of ($0.06) per share for the quarter. Zacks Investment Research also issued estimates for Resverlogix Corp.’s Q3 2017 earnings at ($0.06) EPS, Q4 2017 earnings at ($0.05) EPS and FY2019 earnings at ($0.22) EPS.
Shares of Resverlogix Corp. (TSE:RVX) opened at 1.90 on Thursday. The company’s 50-day moving average is $1.34 and its 200-day moving average is $1.30. The firm’s market cap is $199.90 million. Resverlogix Corp. has a 52-week low of $1.10 and a 52-week high of $2.52.
Resverlogix Corp. Company Profile
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.
Receive News & Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related companies with MarketBeat.com's FREE daily email newsletter.